Enfortumab Vedotin for Previously Treated Advanced Urothelial Carcinoma

Posted by Daniel P. Petrylak, MD | Apr 2021

Daniel P. Petrylak, MD, presented “Enfortumab Vedotin for Previously Treated Advanced Urothelial Carcinoma” for the Grand Rounds in Urology audience in April 2021.

How to cite: Petrylak, Daniel P. “Enfortumab Vedotin for Previously Treated Advanced Urothelial Carcinoma” April 2021. Accessed Apr 2024. https://grandroundsinurology.com/enfortumab-vedotin-for-previously-treated-advanced-urothelial-carcinoma/

Summary:

Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, summarizes his article on the EV-301 study of enfortumab vedotin and its role in making the drug a standard treatment option for patients with urothelial cancer. In 2012, Dr. Petrylak began working on a phase 1 trial of enfortumab which found that the drug had about a 40% response rate in patients with or without checkpoint surgery. He then worked on the EV-201 phase 2 trial, which found about a 40% response rate in patients previously treated with either a platinum-based chemotherapy or checkpoint inhibitor. Dr. Petrylak also worked on the phase 3 study (EV-301), which randomized patients to receive either enfortumab vedotin or standard chemotherapy and found significant overall survival benefits as well as a response rate of about 40% in the enfortumab arm. By confirming phase 1 and phase 2 data, this study earned enfortumab vedotin accelerated FDA approval. Dr. Petrylak does note that the drug has some side effects, including neuropathy and rashes. The video ends with a question and answer session conducted by E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology. Drs. Petrylak and Crawford discuss plans to use enfortumab vedotin earlier in the treatment process, and Dr. Petrylak observes that many studies are working on exactly that, including one looking at using this drug with pembrolizumab as a first-line treatment.

For more from Dr. Petrylak on clinical trials in this area, view his discussion on enfortumab vedotin from last year.

About The Author

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. Dr. Petrylak is a member of the American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), American College of Physicians (ACP), American Association for the Advancement of Science (AAAS), American Urological Association (AUA), and the Southwest Oncology Group (SWOG). After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee. He additionally has led multiple national and international studies in prostate and bladder cancer. Dr. Petrylak’s research interests span both prostate and bladder cancer. He led an investigator-initiated trial of docetaxel and estramustine in castration resistant prostate cancer. The results of this study supported a phase 3 trial of this combination in SWOG led by Dr. Petrylak, which in turn, supported the FDA approval of docetaxel for castration resistant prostate cancer. This was one of the first two trials to demonstrate a survival benefit in this state of disease. Dr. Petrylak has also been instrumental in the development of immunotherapy and targeted therapies for refractory bladder cancer. His work with Enfortumab Vedotin has supported the accelerated and full FDA approval of this drug. Dr. Petrylak received his undergraduate degree from Columbia College and his medical degree from Case Western University School of Medicine. He completed his internship and residency at Albert Einstein College of Medicine and his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. He has authored more than 200 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat